Opdivo Plus Chemo Did Not Improve Progression in EGFR-Mutate

Treatment with Opdivo (nivolumab) and chemotherapy did not significantly improve progression-free survival when compared with chemotherapy alone among some patients with EGFR-mutated metastatic non-small-cell lung cancer.

Related Keywords

United States , Taiwan , China , Japan , South Korea , Spain , France , Singapore , Tagrisso Osimertinib , Ching Kong , News , Lung Cancer , Non Small Cell Lung Cancer , Opdivo , Chemotherapy ,